Publication of the interim analysis from the global phase 3 ORIGIN3 Trial

IgA nephropathy (IgAN) is a rare disease, where your own immune system produces antibodies in the kidney leading to inflammation that, over time can interfere with the kidneys’ ability to filter waste from the blood. 𝗧𝗵𝗲𝗿𝗲 𝗶𝘀 𝗰𝘂𝗿𝗿𝗲𝗻𝘁𝗹𝘆 𝗻𝗼 𝗰𝘂𝗿𝗲 𝗳𝗼𝗿 𝗜𝗴𝗔𝗡, and at least 50% of patients progress to kidney failure or death within 10–20 years of diagnosis. Existing therapies can only slow, not stop, disease progression.

The ORIGIN 3 study is a global, multicentre Phase 3 trial evaluating 𝗮𝘁𝗮𝗰𝗶𝗰𝗲𝗽𝘁, a TACI-Fc fusion protein that blocks BAFF and APRIL—key drivers of IgAN disease progression.

𝗜𝗻𝘁𝗲𝗿𝗶𝗺 𝗮𝗻𝗮𝗹𝘆𝘀𝗶𝘀 𝗳𝗶𝗻𝗱𝗶𝗻𝗴𝘀:
At week 36, atacicept treatment resulted in a 45.7% reduction in the urinary protein-to-creatinine ratio (UPCR) from baseline, as compared with a 6.8% reduction in the placebo group. The between-group difference of 41.8 percentage points in the reduction from baseline in the UPCR was significant and considered clinically meaningful.

𝗦𝗿𝗶 𝗟𝗮𝗻𝗸𝗮 𝗽𝗿𝗼𝘂𝗱𝗹𝘆 𝗰𝗼𝗻𝘁𝗿𝗶𝗯𝘂𝘁𝗲𝗱 to this global trial. RemediumOne coordinated local activities, enrolling 𝟭𝟮 𝗽𝗮𝗿𝘁𝗶𝗰𝗶𝗽𝗮𝗻𝘁𝘀 between July 2024 and February 2025 across five hospitals:
National Hospital of Sri Lanka
Colombo North Teaching Hospital
Kandy National Hospital
Jaffna Teaching Hospital
Kurunegala Teaching Hospital

A heartfelt thank you to our investigators and study teams for their dedication and effort.

We are proud to have supported a study that may bring a much-needed therapeutic option closer to patients worldwide and looking forward to the comprehensive analyses of the full study.

Read the full publication here: https://lnkd.in/g44kiq-g